- The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) improves OS in patients with stage III primary epithelial ovarian cancer.
- Patients with complete surgery show 3-year OS benefit with HIPEC.
Why this matters
- The National Comprehensive Cancer Network recommends incorporation of intraperitoneal therapy into the management of advanced-stage ovarian cancer.
- Previous studies have shown survival benefits with HIPEC in ovarian cancer; however, large-scale, multicenter trials are lacking.
- 584 patients with stage III primary epithelial ovarian cancer were treated with either PCS alone (n=159) or PCS with HIPEC (n=425).
- Funding: National Natural Science Foundation of China.
- Median follow-up: 42.2 months.
- The median OS in HIPEC and PCS-alone group:
- All patients: 49.8 vs 34.0 months (HR, 0.63; P<.001>
- Patients with complete surgery: 53.9 vs 42.3 months (weighted HR, 0.67; P=.02).
- Patients who received incomplete surgery: 29.2 vs 19.9 months (weighted HR, 0.65; P=.03).